Exelixis (NASDAQ:EXEL) CFO Christopher Senner Sells 30,617 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) CFO Christopher Senner sold 30,617 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $43.67, for a total value of $1,337,044.39. Following the completion of the sale, the chief financial officer directly owned 976,092 shares in the company, valued at $42,625,937.64. This trade represents a 3.04% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Exelixis Trading Up 0.9%

EXEL stock opened at $44.47 on Thursday. The stock has a market capitalization of $11.55 billion, a P/E ratio of 16.05, a price-to-earnings-growth ratio of 0.99 and a beta of 0.42. Exelixis, Inc. has a 12 month low of $32.38 and a 12 month high of $49.62. The firm has a 50-day moving average price of $43.77 and a 200-day moving average price of $41.13.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.20. The company had revenue of $598.66 million for the quarter, compared to analyst estimates of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. The firm’s revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the firm posted $0.55 EPS. As a group, equities analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Hedge Funds Weigh In On Exelixis

Hedge funds have recently made changes to their positions in the stock. Richardson Financial Services Inc. boosted its holdings in Exelixis by 95.1% in the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 292 shares during the last quarter. Anchor Investment Management LLC raised its holdings in Exelixis by 500.0% during the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 500 shares during the last quarter. Motiv8 Investments LLC acquired a new position in shares of Exelixis in the 4th quarter worth approximately $26,000. Root Financial Partners LLC bought a new stake in shares of Exelixis in the 3rd quarter valued at $28,000. Finally, Acumen Wealth Advisors LLC acquired a new stake in shares of Exelixis during the fourth quarter worth $29,000. 85.27% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. TD Cowen reissued a “buy” rating on shares of Exelixis in a report on Wednesday, November 5th. Truist Financial set a $51.00 target price on Exelixis in a research report on Wednesday, January 14th. Wells Fargo & Company lifted their price target on Exelixis from $30.00 to $35.00 and gave the company an “equal weight” rating in a research note on Wednesday, February 11th. Wolfe Research started coverage on Exelixis in a report on Tuesday, November 18th. They set a “peer perform” rating on the stock. Finally, Oppenheimer reiterated a “market perform” rating and issued a $36.00 price objective on shares of Exelixis in a report on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $47.11.

Key Headlines Impacting Exelixis

Here are the key news stories impacting Exelixis this week:

• Neutral Sentiment: Summary: Multiple SEC Form 4 filings show insider sales totaling roughly $9 million across several executives and directors; the filings do not state the motivation (could be pre‑planned sales, diversification, or personal liquidity). CFO Christopher Senner filings
• Negative Sentiment: CFO Christopher J. Senner sold 34,278 shares on Feb 13 at an average $43.00 (~$1.47M) and 30,617 shares on Feb 17 at $43.67 (~$1.34M); combined reduction of ~3.18% and 3.04% of his holdings in separate filings. SEC filing
• Negative Sentiment: EVP Patrick J. Haley sold 67,814 shares on Feb 17 at an average $43.52 (~$2.95M), a ~15.08% cut to his stake. SEC filing
• Negative Sentiment: Director Bob Oliver sold 30,250 shares on Feb 13 at an average $43.81 (~$1.33M), reducing his position by ~58.9%. SEC filing
• Negative Sentiment: SVP Brenda Hefti sold 18,669 shares on Feb 18 at an average $44.01 (~$0.82M), trimming her holding by ~16.2%. SEC filing
• Negative Sentiment: Director Sue Gail Eckhardt sold 3,856 shares on Feb 13 at an average $43.79 (~$0.17M), an ~18.0% reduction of her stake. SEC filing

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.